Latest News
Iambic Therapeutics, Inc.
- Form 4 Iambic Therapeutics: Thomas F. Miller (Director, CEO) For: 14 October
- Nvidia-backed Iambic stock is up 16% in Nasdaq debut after $150 million IPO
- Iambic, an AI drug discovery specialist, banks $150M in an IPO
- Iambic Therapeutics prices IPO at $16 per share to raise $150 million
- The drug disconnect between Iambic and Isomorphic
- Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO
- Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
- Iambic aims for $135M IPO to push cancer drugs through clinic
- Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
- NVIDIA-Backed Iambic Therapeutics Files for IPO
- Iambic Therapeutics Starts IPO Effort On Broad Collaboration Relationships (Pending:IAM)
- AI drug hunter Iambic files for Nasdaq IPO
Headlines from the last 30 days, linking to the original publishers. See all market news →